Ocera Completes Interim Analysis of OCR-002 in Phase 2b

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Ocera Completes Interim Analysis of OCR-002 in Phase 2b STOP-HE Study for the Treatment of Acute Hepatic Encephalopathy

PALO ALTO, Calif., April 1, 2015 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (Nasdaq: OCRX ), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced successful completion of a planned interim analysis of its STOP-HE study, a double-blind placebo-controlled study of OCR-002 in patients with acute hepatic encephalopathy (HE). The study's independent Data Monitoring Committee (DMC) reported that the trial is not futile and no drug-related safety signals have been observed in the study. Based on the DMC's recommendation, Ocera will continue the STOP-HE study and will increase target enrollment from 140 patients to approximately 230 patients. The Company remains blinded to data reviewed by the DMC in the interim analysis.

"We are encouraged that these early data suggest a promising treatment effect with OCR-002 and a reduction in time to recovery for patients with acute hepatic encephalopathy," said Linda S. Grais, M.D., Chief Executive Officer of Ocera. "While the new enrollment target will extend our timelines, we believe that this will enhance the likelihood of achieving a positive result at the end of the study. Treatment options for these severely ill patients are sub-optimal. We believe OCR-002 may help these patients recover more rapidly from acute episodes of HE, as well as provide pharmacoeconomic benefit to hospitals, payors and the healthcare system. With the new enrollment target, we anticipate completing this trial in the second half of 2016."

HE is a serious, rare, progressive and episodic complication of liver cirrhosis, or liver failure, marked by mental changes including confusion, impaired motor skills, disorientation in time and space, and in its more severe form, stupor, coma and even death.

"This positive recommendation is important for the advancement of newer therapies for seriously ill HE patients who are not responding to current standard of care," commented Jasmohan Bajaj, M.D. Dr. Bajaj, a STOP-HE study investigator, is a gastroenterologist and transplant hepatologist at Virginia Commonwealth University and the McGuire Veterans Affairs Medical Center in Richmond, Virginia. "HE in the acute care setting remains a challenging clinical condition. OCR-002 is a novel, promising therapeutic option for HE and we look forward to the speedy completion of this trial."

STOP-HE Study Design

STOP-HE is a placebo-controlled, randomized, double-blind clinical trial designed to evaluate the safety, pharmacokinetics and efficacy of intravenously-administered OCR-002 in resolving neurocognitive symptoms of acute HE in hospitalized cirrhotic patients with elevated ammonia. Either OCR-002 or placebo is administered to patients intravenously for up to five days along with standard of care. The OCR-002 arm has been dosed with 20, 15, or 10 grams over 24 hours based on the patient's degree of liver impairment in order to normalize drug exposure. The primary efficacy endpoint is time to meaningful clinical improvement analyzed using a 0.05 level 2-sided log-rank test of equality of time to event curves with 80% power. The pre-specified interim reassessment of sample size was conducted to assess the adequacy of the planned sample size of the study (n=140) to detect a difference between treatment arms in the median time to improvement. Using a sample size of 140 patients, the estimated median time to improvement was driven by an assumed response rate of 68% vs. 45% in OCR-002 vs. placebo arms, respectively, resulting in an approximately 50% faster median time to meaningful clinical improvement over a five day treatment period.

About Ocera

Ocera Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of OCR-002 (ornithine phenylacetate) in both intravenous and oral formulations. OCR-002 is an ammonia scavenger and has been granted orphan drug designation and Fast Track status by the U.S. Food and Drug Administration (FDA) for the treatment of hyperammonemia and resultant hepatic encephalopathy in patients with acute liver failure and acute-on-chronic liver disease. For additional information, please see www.ocerainc.com .

Forward-Looking Statements

This press release contains "forward-looking" statements, including, without limitation, all statements related to the OCR-002 clinical development program, including but not limited to the potential benefits of OCR-002 to help people with acute and chronic orphan liver diseases and the expected timing of the completion of enrollment of its "STOP-HE" study. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believe," "expected," "hope," "plan," "potential," "will" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Ocera's current expectations. Forward-looking statements involve risks and uncertainties and Ocera's actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, including those risks and uncertainties discussed under the heading "Risk Factors" in Ocera's Annual Report on Form 10-K for the year ended December 31, 2014 and subsequent filings with the SEC. All information in this press release is as of the date of the release, and Ocera undertakes no duty to update this information unless required by law.

Susan Sharpe Ocera Therapeutics, Inc. 919-328-1109

Scroll down for more posts ▼

Top 10 Most Recent News Articles

CJ BIO Bets on Better Taste for Cleaner Food Labels

Updated Category News Views 92

A bland reduced-salt sauce can wreck months of product development in one spoonful. That unglamorous reality sits underneath CJ BIO's November 17-19 appearance at Fi Europe 2026 in Frankfurt, where the company is pitching food makers on a simple but stubborn proposition: healthier-looking labels cannot come at the expense of taste. Flavor Is Still the Gatekeeper CJ BIO is...

Continue Reading
Sunbit’s 2027 Loan Push Meets an NVIDIA-Fueled Tape

Updated Category News Views 188

Credit Is About to Enter Sunbit’s Growth Story Sunbit has spent years building a point-of-sale fintech footprint, and the numbers it cited on November 18 make the next step harder to dismiss as mere marketing fluff. The company says it has topped 400,000 activated cardholders and 50,000 merchants, while expecting more than $440 million in fiscal 2026 sales on greater...

Continue Reading
Tactical Tomahawk Motor Deal Puts Propulsion in Focus

Updated Category News Views 227

A missile program lives or dies on unglamorous hardware, and solid rocket motors are about as unglamorous as it gets until somebody cannot build enough of them. Raytheon has awarded Ursa Major and Avio USA a joint contract to develop solid rocket motors for the U.S. Navy’s Tactical Tomahawk missile program. That is the whole headline, and it matters more than the thin...

Continue Reading
Knowles Expands Its Teacher Pipeline With 39 Fellows

Updated Category News Views 62

Thirty-Nine Teachers Is Not a Trivial Signal Thirty-nine new math and science teachers may not rattle public markets, but it says plenty about where the real strain sits in American education. The Knowles Teacher Initiative has named its 2026 Teaching Fellowship class, its largest ever, and the timing is dead serious: schools are still wrestling with recruiting and...

Continue Reading
Somerville’s New Immersive Bet Has Room to Grow Locally

Updated Category News Views 74

A passcard, a hidden door, and 12,000 square feet of mischief have landed at Somernova. Edge of Elsewhere, the new flagship attraction from Boston-area creative studio Midnight Mansion, is open in Somerville’s Union Square as of November 18, 2026. It is part interactive art installation, part puzzle game, part physical story world. That sounds delightfully odd, which is...

Continue Reading
Teachers in Space Takes Its Classroom Model Orbital

Updated Category News Views 60

Two teachers strapped into a research flight may sound like a glossy space-age photo op, but the useful part of this plan sits back in the classroom with the students staring at the data. Teachers in Space wants to send two educators aboard a Virgin Galactic research flight expected in 2027, and it is raising $2 million to fund the broader educational program and mission....

Continue Reading
America's Group Adds Swansea to Its UK Auction Map

Updated Category News Views 117

A Welsh Lane Joins a Larger Road Port Talbot just became a small but telling dot on America's Group's international map. The company has acquired Swansea Motor Vehicle Auction Limited, a long-standing South Wales wholesale and remarketing operation, and plans to run it under the G3 brand. This is not the sort of deal that makes markets levitate. It is the sort that tells...

Continue Reading
Cadence Marks $2.7 Million for St. Jude Family Care

Updated Category News Views 112

Small Wheels, Serious Purpose Tiny tricycles, flour-dusted bake-sale tables, and family pledges have pushed Cadence Education’s St. Jude partnership to $2.7 million since 2018. That number is not a flashy balance-sheet item, nor should anybody try to dress it up as one. It is the accumulated result of school communities showing up year after year, and in a sector built...

Continue Reading
Marelli’s Two Awards Put Practical Auto Tech in Focus

Updated Category News Views 89

Two trophies in Novi do not fill an order book, but Marelli’s latest pair says something useful about where automotive suppliers are trying to earn their keep. The company collected a 2026 Automotive News PACE Award for HorizonView and a PACE Pilot Award for Affordable 5G RedCap at the November 17 ceremony. One is already deployed in production; the other is a...

Continue Reading
Cytonics Refines CYT-108 Trial Plan With Decade OA Data

Updated Category News Views 83

A Better Map Is Not a Working Drug Knee osteoarthritis has chewed up plenty of promising development plans because the disease moves at an aggravatingly uneven crawl. Cytonics has done something sensible before pushing deeper into CYT-108: it went back to long-term untreated patient data and asked which knees actually deteriorate fast enough for a trial to detect...

Continue Reading

Top 5 Most Recently Viewed Articles

Current Trends in Short Interest Impacting PayPal Stock

Updated Category News Views 262

Understanding PayPal Holdings Inc and Its Market Position PayPal Holdings Inc (NYSE: PYPL) remains a prominent player in the digital payments space, continuing to see fluctuations in its market sentiment. Recently, the company has noted a significant increase in short interest as a percentage of float, climbing by 11.57%. This rise has brought the total number of shares...

Continue Reading
WillScot Plans Upcoming Earnings Call and Webcast for Q1

Updated Category News Views 152

WillScot Holdings Corporation to Share Q1 Results WillScot Holdings Corporation, a renowned leader in providing innovative temporary flexible space solutions, has announced its schedule for releasing the financial results for the first quarter of 2025. This eagerly anticipated announcement is set to take place on May 1, 2025, after market close, allowing investors and...

Continue Reading
Denarius' Bold Move: Debentures Target Early Exit

Updated Category News Views 53

Treading Against Debentures: Denarius' Maneuver Denarius Metals Corp. doesn't seem keen on playing it safe with convertible debentures tying up its business. Jaw-dropping numbers in news like this make you stop and wonder: Is this strategy brilliance, or just a roll of the dice? Time-Pressured Decisions Denarius Metals, trading as OTCQX: DNRSF, has kicked off a whirlwind...

Continue Reading
Katten Partners Recognized Among Top Experts in Crypto Sector

Updated Category News Views 185

Katten Partners Shine in Crypto Industry Recognition Katten, a well-respected law firm, has gained significant attention for its leadership in the evolving digital asset landscape. Three of its distinguished partners have been recognized by Citywealth, a leading publication in the private wealth sector, for their exceptional contributions to the cryptocurrency domain. The...

Continue Reading
Anticipating Logitech International's Earnings Success

Updated Category News Views 160

Anticipating Logitech International's Earnings Success Logitech International (NASDAQ: LOGI) is gearing up for its next quarterly earnings announcement, and investors are keenly observing potential developments. As the company prepares to report earnings, expectations are high for positive news regarding financial forecasts and results. Analyst Predictions for Earnings...

Continue Reading